Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound
NCT ID: NCT00631553
Last Updated: 2008-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2006-06-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
perflutren lipid microspheres
1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and females
* Ages 18-65 years old
Exclusion Criteria
* H/o kidney disease
* H/o congestive heart failure, ischemic heart disease, severe pulmonary disease or allergy to the drug
* H/o any cardiovascular disease
* Abnormal liver function (liver function tests out of specified ranges)
* Screening urinalysis which indicates infection or inflammation
* Taking regular medications (except for over-the-counter vitamins or hormonal contraceptives.)
* Taking supplements, like protein shakes
* Unwilling or unable to eat chicken (used as protein meal)
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
University of Virginia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Virginia Dept of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kambiz Kalantarinia, MD
Role: PRINCIPAL_INVESTIGATOR
University of Virginia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Virginia Health System
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kalantarinia
Role: primary
Ratliff
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12014
Identifier Type: -
Identifier Source: org_study_id